Hybrid bivalent ligands with opiate and enkephalin pharmacophores

Bivalent ligands consisting of oxymorphamine and [D-Glu2]enkephalin pharmacophores linked through a spacer attached to the 6-amino group of the former and D-Glu of the latter were synthesized in an effort to investigate the possible coexistence of mu and delta recognition sites in the same opioid receptor complex. Of the two bivalent ligands (1,2) synthesized, only 1 had substantially greater antinociceptive potency in mice than its monovalent analogues (1a, 1b). Testing of 1, 1a, and 1b in the guinea pig ileum preparation (GPI) revealed a potency profile similar to that found in vivo, whereas no correlation was observed in the mouse vas deferens (MVD). Binding data indicated the same rank-order affinities at delta receptors as the opioid activities in the GPI and in mice. However, mu binding exhibited no relationship with activity. These results are consistent with the simultaneous occupation of mu and delta by a single bivalent ligand 1, but they are also in harmony with the interaction of 1 with an opioid receptor and an accessory binding site.

Structure-activity relationships of cyclic opioid peptide analogues containing a phenylalanine residue in the 3-position

Ten analogues of the highly mu-receptor selective cyclic opioid peptide H-Tyr-D-Orn-Phe-Asp-NH2 (1) were synthesized by the solid phase method and were characterized in vitro in mu- and delta-receptor representative binding assays and bioassays. These cyclic analogues are structurally related to the linear opioid peptides dermorphin and beta-casomorphin (morphiceptin), which also contain a phenylalanine residue in the 3-position of the peptide sequence. The obtained results indicate that analogous structural modifications (configurational inversion at positions 2, 3, and 4 or N alpha-methylation of Phe3) in cyclic peptide 1 and in dermorphin-related peptides had qualitatively the same effect on opioid activity, whereas the corresponding modifications in beta-casomorphins had the opposite effect. These findings can be interpreted to indicate that the mode of receptor binding of H-Tyr-D-Orn-Phe-Asp-NH2 is identical with that of dermorphin, but differs from that of beta-casomorphins. The side-chain length of the aromatic residue in position 3 of cyclic analogue 1 was shown to be critical for receptor affinity and selectivity, suggesting that mu- and delta-receptors differ from one another in the relative topographical disposition of the binding sites for the Tyr1 tyramine moiety and the Phe3 aromatic ring. Cyclic lactam analogue H-Tyr-D-Asp-Phe-A2bu-NH2, containing a reduced-size (12-membered) ring structure, showed increased mu-receptor selectivity, whereas the more flexible, cystine-containing analogue H-Tyr-D-Cys-Phe-Cys-NH2 (11-membered ring) was less selective. The latter results indicate that both ring size and ring flexibility affect receptor affinity and selectivity.

Synthesis and biological activity of some glucose-enkephalin conjugates

Two O-glucopeptides, H-Tyr(beta-D-Glc)-Gly-Gly-Phe-OH(10) and H-Tyr(beta-D-Glc)-Gly-Gly-Phe-Leu-OH (11), having the amino acid sequence of enkephalin, were synthesized to determine the influence of the carbohydrate molecule on the biological activity and conformation of these opioid peptides. The synthesis were carried out in a stepwise and/or direct manner by fusing the activated O-glucosylpseudourea intermediate with suitably protected amino acid or peptide derivatives, followed by hydrogenolytic removal of protecting groups. The pure compounds were tested for opiate-like activity by using the guinea pig ileum (GPI) and mouse vas deferens (MVD) preparations.

Superactive analogs of the atrial natriuretic peptide (ANP)

Three analogs of the atrial natriuretic peptide ANP(105-126), lacking the N-terminal exocyclic peptide segment and containing 2-mercaptoacetic acid, 3-mercaptopropionic acid or 4-mercaptobutyric acid in place of the cysteine residue in position 105 of the peptide sequence, were synthesized by the solid-phase method. The resulting des-amino analogs showed 2 to 4 times higher diuretic/natriuretic activity than the most active natural ANP and displayed a potent hypotensive effect as well. All three analogs were relatively less potent in various in vitro bioassays and in a binding assay, indicating that their high activities in vivo may be due to resistance to enzymatic degradation and to reduced non-specific tissue adsorption. These compounds not only will serve as useful pharmacologic tools but also represent prototypes for the development of further reduced-size ANP analogs.

Side chain to side chain cyclization of an enkephalin analog results in loss of opioid receptor selectivity

The cyclic enkephalin analog H-Tyr-D-Lys-Gly-Phe-Glu-NH2 (I) and the structurally related open chain analogs H-Tyr-D-Nle-Gly-Phe-Gln-NH2 (II) and H-Tyr-D-Lys(For)-Gly-Phe-Abu-NH2 (III) were tested in mu and delta opioid receptor-representative binding assays and bioassays. Whereas both linear analogs showed a pronounced preference for mu receptors over delta receptors, the conformationally restricted cyclic peptide I was found to be unselective. This finding represents the first reported example of a peptide cyclization resulting in a loss of receptor selectivity. From this and earlier studies, it was concluded that the receptor selectivity of cyclized peptide analogs relative to that of their linear correlates may depend on the size and relative rigidity of their ring structures.

Synthesis and activity profiles of atrial natriuretic peptide (ANP) analogs with reduced ring size

Three deletion analogs of the atrial natriuretic peptide, [desGly-120]-ANP(103-126), [desLeu119, desGly120]ANP(103-126) and [desGly118,120,-desLeu119]-ANP(103-126), were synthesized by the solid-phase method. Successive elimination of the non-functional residues in positions 120-118 of the peptide sequence resulted in a progressive potency reduction in the rabbit aorta assay, in the bioassay monitoring suppression of aldosterone secretion from bovine zona glomerulosa cells and in a binding assay based on displacement of radioiodinated ANP(101-126) from bovine zona glomerulosa cell membranes. The fact that the deletion analogs showed quantitatively different relative potencies in each of the three in vitro assay systems was interpreted as further evidence in support of the existence of two or more classes of ANP receptors or binding sites.

In vitro activity profiles of cyclic and linear enkephalin pseudopeptide analogs

The peptide bond in the 4-5 position of the cyclic and linear enkephalin analogs H-Tyr-cyclo[-D-Lys-Gly-Phe-L(or D)-Leu-] and H-Tyr-D-Ala-Gly-Phe-L(or D)-Leu-OH was replaced by a thiomethylene ether linkage. Each of the configurational isomers of the cyclic pseudopeptide H-Tyr-cyclo[-D-Lys-Gly-Phe psi [CH2S]L(or D)-Leu-] showed high potency in both the guinea pig ileum and the mouse vas deferens assay and, therefore, had no preference for either mu- or delta-opioid receptors, in contrast to the cyclic parent peptides H-Tyr-cyclo[-D-Lys-Gly-Phe-L(or D)-Leu-] which are mu-receptor selective. The loss of selectivity observed with the cyclic pseudopeptides may be due to the greater flexibility of their 18-membered ring structures as a consequence of the peptide bond substitution. The linear pseudopeptide analogs were both less potent and less delta-receptor selective than their parent compounds. These results indicate that thiomethylene ether peptide bond replacements can have a pronounced effect on the activity profile of peptide hormones and neurotransmitters.

Synthesis and activity profiles of novel cyclic opioid peptide monomers and dimers

A new family of cyclic opioid peptide analogues of the type H-Tyr-D-Xxx-Phe-Yyy-NH2 was obtained through amide bond formation between side chain amino and carboxyl groups of Orn (or Lys) and Asp (or Glu) residues substituted in positions 2 and 4 of the peptide sequence. Peptides were synthesized entirely by solid-phase techniques, and aside from the cyclic monomers, cyclization on the benzhydrylamine resin also produced side chain linked antiparallel cyclic dimers due to intersite reaction. In binding studies based on displacement of mu- and delta-opioid receptor-selective radiolabels from rat brain membranes the highly rigid cyclic monomer H-Tyr-D-Orn-Phe-Asp-NH2 (1) (containing a 13-membered ring) was shown to be one of the most selective mu-receptor ligands reported to date, whereas the corresponding cyclic dimer, (H-Tyr-D-Orn-Phe-Asp-NH2)2 (1a), was nonselective. The difference in receptor selectivity observed between 1 and 1a is a consequence of the different conformational constraints present in the cyclic monomer and dimer. In contrast to 1, the conformationally less restricted cyclic analogue H-Tyr-D-Lys-Phe-Glu-NH2 (3) (15-membered ring) showed no receptor preference. Qualitatively similar potency relationships were observed in the guinea pig ileum (GPI) and mouse vas deferens (MVD) bioassays. However, in the case of analogues 1 and 3 discrepancies observed between potencies determined in the mu-receptor-representative GPI bioassay and in the mu-receptor-selective binding assay seemed to indicate that the conformational constraint present in these compounds may produce an "efficacy" enhancement. Corresponding analogues containing an Asp (or Glu) residue in the 2-position and an Orn (or Lys) residue in the 4-position showed similar selectivity relationships, but better agreement between bio- and binding assay data. These results indicate that incorporation of various conformational constraints into opioid peptides permits manipulation of both receptor selectivity and efficacy.

A novel side-chain-linked antiparallel cyclic dimer of enkephalin

The dimeric cyclic enkephalin analog, (H-Tyr-D-Lys-Gly-Phe-Glu-NH2)2, was isolated as a second major component from the crude product obtained in a solid-phase synthesis of the corresponding cyclic monomer, H-Tyr-D-Lys-Gly-Phe-Glu-NH2. In comparison with [Leu5]enkephalin the cyclic dimer is about equipotent in assays representative for mu-opioid receptor interactions and 1/10 as potent at the delta-receptor. The fact that the enkephalin dimer shows a receptor selectivity pattern distinct from that of the cyclic monomer and of the corresponding linear analog suggests that cyclodimerization via side-chain linkages might be generally useful as a means to produce shifts in the activity profiles of peptide hormones and neurotransmitters.

Synthesis and biological activity of a linear fragment of the atrial natriuretic factor (ANF)

A linear fragment of the atrial natriuretic factor, ANF(106-125), unable to form an intramolecular cystine bridge, was synthesized by the solid-phase method. The fragment showed smooth muscle relaxant activity in the rabbit aorta and chick rectum assays, an inhibitory effect on aldosterone secretion from bovine adrenal zona glomerulosa cells, and had affinity for specific ANF receptors located in zona glomerulosa cell membranes. The potency of ANF(106-125) in these four assay systems was about two to three orders of magnitude lower than that of ANF(103-125) which contains the intact cyclic structure. The obtained results indicate that the disulfide linkage stabilizes the bioactive conformation of ANF peptides but is not an absolute requirement for biological activity.

Localization of immunoreactive synthetic atrial natriuretic factor (ANF) in the heart of various animal species

The localization of two synthetic fragments of the C-terminal portion of atrial natriuretic factor: Arg 101-Tyr 126 which displays full biological activity and Leu 94-Arg 109 which is completely devoid of biological activity, has been investigated by immunohisto- and immunocytochemical methods in the heart of mammals (rat, mouse, guinea pig, hamster, rabbit, cat, dog, man) and nonmammalian vertebrates toad (Bufo marinus), frog (Rana catesbeiana), fish (Cyprinus carpio, Puntius schwanenfeldi, Cichlosoma biocellatum, Carrasius auratus), snake (Python reticulatus) and hen. Antibodies against the synthetic fragments of ANF were raised in rabbits and used either for immunofluorescence (Coons' technique), immunohistochemistry (unlabeled antibody technique) or immunocytochemistry (protein A-gold technique). Results obtained by immunofluorescence and by the unlabeled antibody technique were similar: antibodies against Arg 101-Tyr 126 ANF allowed visualization of granulated cardiocytes in the atria of all mammals. While the reaction was very strong in rat and mouse, it was less so in the rabbit and very weak in all other species studied including man. Antibodies against Leu 94-Arg 109 ANF produced a reaction only in the rat and mouse. In nonmammalian vertebrates, the reaction was always much stronger in atria than ventricles of all species with both antibodies.

Synthesis and biological activity of linear and cyclic enkephalins modified at the Gly3-Phe4 amide bond

As part of our continuing effort to define structure-activity relationships for enkephalin and design enzymatically resistant analogs, we report the synthesis and biological activities of linear and cyclic enkephalin analogs modified at the Gly3-Phe4 amide bond. The partial retro-inverso enkephalin analog Tyr-D-Ala-gGly-(R,S)-mPhe-Leu-NH2 and its cyclic counterpart, Tyr-cyclo[D-A2 bu-gGly-(R,S)-mPhe-Leu-], were synthesized as diastereomeric mixtures using solution methodology. The racemic benzylmalonate allowed the linear analog to be synthesized by fragment coupling at the reversed bond. Cyclization of the second analog was carried out at high concentration, eliminating formation of polymer by the use of an insoluble base. All gem-diaminoalkyl residues were prepared by conversion of peptidyl amides with benzene iodonium bis(trifluoroacetate). Diastereomers of both compounds were separable by reverse phase HPLC but those of the linear compound racemized rapidly under conditions of testing and were therefore tested together. All analogs tested had activities ranging from 6 to 14% of the activity of Leu enkephalin, indicating that the Gly3-Phe4 amide bond is important, though not crucial, for receptor binding.

Generalization tests with intraventricularly applied pro-enkephalin B-derived peptides in rats trained to discriminate the opioid kappa receptor agonist ethylketocyclazocine

Rats were trained in a two-lever food-reinforced procedure to discriminate between the effects of saline and the opioid kappa receptor agonist ethylketocyclazocine. After acquisition of this discrimination, generalization tests with opioid peptides such as beta-endorphin, alpha-neoendorphin, dynorphin A and some dynorphin-derived peptides were conducted. The rats dose-dependently generalized the effects of intracerebroventricularly injected ethylketocyclazocine but not beta-endorphin, alpha-neoendorphin, dynorphin A1-8, dynorphin A1-13, D-Cys2-L-Cys5-dynorphin A1-13 or dynorphin A. D-Cys2-L-Cys5-dynorphin A1-13, in contrast to dynorphin A itself, dose-dependently caused analgesia and catatonia that was reversible with naloxone. Studies into the receptor preference of this derivative, using the technique of "selective tolerance", revealed that this dynorphin derivative is almost devoid of kappa-receptor activity.

Characterization of specific receptors for atrial natriuretic factor in bovine adrenal zona glomerulosa

We have recently shown that synthetic rat atrial natriuretic factor (ANF) directly inhibits mineralocorticoid and glucocorticoid secretion in cultured bovine adrenal cells with a potency of 100 pM. [125I]iodo-ANF was used in the present study to characterize potential receptor sites in bovine zona glomerulosa membranes. ANF binds to a class of high affinity binding sites with a pK of 10.2 and a density of 1.3 pmol/mg protein. Detailed competition curves with ANF document a class of high affinity sites with a pK of 10.2 and also a second class of lower affinity sites with a pK of 8.5. Nonspecific binding amounts to less than 10% of [125I]iodo-ANF binding at concentrations less than 100 pM. High affinity binding of [125I]iodo-ANF is reversible with a half-time of association of 15 minutes at 25 pM and a half-time of dissociation of 140 minutes. Monovalent cations Na, Li and K equipotently enhance [125I]iodo-ANF specific binding. Divalent cations Mg, Ca and Mn also increase [125I]iodo-ANF specific binding, with Mn being the most active cation. No effect of guanine nucleotide could be detected on ANF binding. The binding of [125I]iodo-ANF is very specific and is not inhibited by 1 microM angiotensin II, ACTH, VIP, somatostatin, Leu-enkephalin, dynorphin or by the N-terminal of POMC. The N-terminal fragment ANF-(1-16) is also completely inactive. Reduction of the disulfide bridge of ANF inactivates the peptide. This enabled the development of a highly specific radio-receptor assay for ANF with a minimum detectable dose of 2 femtomoles. The results document the specific receptor involved in the potent inhibitory effect of ANF on adrenal steroidogenesis and indicate that bovine adrenal zonal glomerulosa provide a highly sensitive system for studying the recently discovered atrial natriuretic factor.

Activity profiles of novel side-chain to side-chain cyclized opioid peptide analogs

A new family of opioid peptide analogs cyclized through amide bond formation between side-chain amino and carboxyl groups was tested in mu- and delta-opioid receptor selective bio- and binding assays. Within the series of compounds investigated considerable variation in potency and receptor selectivity was observed as a consequence of the introduced conformational restrictions. In particular, the cyclic analogs H-Tyr-D-Glu-Gly-Phe-Lys-NH2 and H-Tyr-D-Glu-Phe-Lys-NH2 showed high preference for mu-receptors over delta-receptors. The development of highly selective receptor ligands constitutes one of the most important prerequisites in efforts aimed at correlating the various types of opioid receptors with specific opioid activities. Recently, the principle of conformational restriction has been successfully applied in the development of selective opioid peptide analogs. In particular, cyclic enkephalin analogs selective for either mu-receptors (1) or delta-receptors (2) have been reported. In the present paper we describe the activity profiles of a new family of side-chain to side-chain cyclized opioid peptide analogs which were obtained through substitution of an alpha, omega-diamino acid and a glutamic or aspartic acid residue in appropriate positions followed by amide bond formation between the side-chain amino and carboxyl groups (cf. Table I). The syntheses of the analogs have been reported elsewhere (3).

Evidence for agonist-induced interaction of angiotensin receptor with a guanine nucleotide-binding protein in bovine adrenal zona glomerulosa

Previous studies have documented that high affinity binding of [125I]angiotensin II to adrenal cortex receptors was modulated by guanine nucleotides. Since in other receptor systems, similar properties of hormone-receptor interactions were shown to be specific for agonists, we studied the differential binding characteristics of agonists and antagonists to this receptor using a new radiolabeled antagonist [125I] [Sar1,Ile8] angiotensin II. Receptor saturation studies indicate that the antagonist is binding to a homogeneous population of sites with a Kd of 0.6-2.0 nM and with a receptor density around 1 pmol/mg of protein. Competition curves using unlabeled antagonists are characterized by a slope factor of 1 and a single Kd of 1-3 nM. Addition of guanylylimidodiphosphate to the assay is absolutely without effect on radiolabeled antagonist binding. In contrast, competition curves using the full agonists angiotensin II, [Sar1]angiotensin II, angiotensin III, and [des-Arg]angiotensin III display slope factors of 0.79, 0.87, 0.70, and 0.84, respectively. These curves can be explained by two apparent forms of the receptor having high and low affinity for the agonist. The higher affinity form associated with these four agonists is characterized by a Kd of 1.2 nM, 0.25 nM, 0.8 nM, and 3 microM, and corresponds to 60, 56, 42, and 25% of angiotensin II-binding sites, respectively. The other form displays 13- to 33-fold lower affinity. Addition of guanine nucleotide to the assay results in a 2-4-fold shift to the right and a steepening (slope factor 0.9-1.0) of agonist competition curves. Angiotensin II receptors, occupied by the full agonist [131I] [Sar1] angiotensin II or by the antagonist [125I] [Sar1, Ile8]angiotensin II, were then solubilized with the nonionic detergent octylglucoside. Dissociation of the agonist [131I] [Sar1] angiotensin II from solubilized receptors is enhanced by guanylylimidodiphosphate or sodium acetate, while dissociation of the antagonist [125I] [Sar1, Ile8]angiotensin II displays little sensitivity towards guanine nucleotides or increased ionic strength. Inclusion of bile salts in the solubilization medium preferentially destabilizes receptor-bound agonist, presumably by interfering with protein-protein interactions required for high affinity agonist binding. Separation of radiolabeled agonist and antagonist-occupied solubilized receptor complexes by steric exclusion high performance liquid chromatography reveals that the agonist-occupied receptor complex behaves as a larger protein than the antagonist-occupied receptor complex.(ABSTRACT TRUNCATED AT 400 WORDS)

Radioimmunoassay of atrial natriuretic factor (ANF) in rat atria

We describe a solid phase radioimmunoassay for atrial natriuretic factor (ANF) and its application for measurement of this peptide in homogenates of rat atria. The method uses a synthetic 26 amino-acid fragment (8-33 ANF) of the native peptide. Sample (or standard) are incubated with the rabbit anti-8-33 ANF antiserum in peptide (8-33 ANF)-coated wells. Then an excess of I125 goat anti-rabbit IgG is added. The radioactivity bound is directly proportional to the amount of ANF present. The concentration of immunoreactive ANF has been found to be about 4 times higher in the right atrium than in the left atrium of the rat.

1H n.m.r. investigation of conformational features of cyclic enkephalinamide analogs

The conformational basis for the differing opioid receptor selectivities of the cyclic cystine-containing analogs, [D-Cys2, D(or L)-Cys5] enkephalinamide and the related penicillamine-containing analogs, [D-Pen2, D(or L)-Cys5] enkephalinamide (penicillamine = beta, beta dimethylcysteine) was investigated by 1H n.m.r. in aqueous solution. Comparison of chemical shift, temperature dependence of amide proton chemical shift, and coupling constant data suggests similar overall conformations for corresponding penicillamine- and cystine-containing analogs. Differences in conformation and flexibility do appear in the carboxamide terminal region of the corresponding analogs, which may account for their selectivities for different classes of opioid receptors.

Evidence of a peptide backbone contribution toward selective receptor recognition for leucine enkephalin thioamide analogs

The in vitro opioid activities of a series of leucine enkephalin analogs containing a thioamide linkage in place of the peptide bond at various positions of the backbone were determined in mu- and delta-receptor-selective bio- and binding-assays. Thioamide substitution in the 1-2 position resulted in an inactive compound, whereas the same modification in the 2-3 and 4-5 position produced potency enhancement. Most interestingly, the 2-3 modified analog showed a 3 to 5 times higher preference for delta- over mu-receptors than natural leucine enkephalin. These results suggest that subtle backbone modifications can have a profound effect on receptor affinity and selectivity of biologically active peptides.

Isolation, structure, and synthesis of a human seminal plasma peptide with inhibin-like activity

A basic peptide isolated from pooled human seminal plasma exhibited inhibin-like activity by suppressing pituitary follicle-stimulating hormone secretion in vitro and in vivo. The peptide has been characterized and sequenced, and a 31-amino-acid synthetic replicate showed full biological activity in vitro.

Cyclic and acyclic partial retro-inverso enkephalinamides: Mu receptor selective enzyme resistant analogs

The cyclic partial retro-inverso modified enkephalins, H-Tyr-cyclo[-D-Glu-Gly-gPhe-D-Leu-] (I), H-Tyr-cyclo[-D-A2bu-Gly-gPhe-R&S-mLeu-] (IIf, IIs), H-Tyr-cyclo[-D-Glu-Gly-Phe-gLeu-] (III), and their corresponding acyclic analogs, H-Tyr-D-Ala-Gly-gPhe-D-Leu-For (Ia), H-Tyr-D-Ala-Gly-gPhe-R,S-mLeu-NH2 (IIa), H-Tyr-D-Ala-Gly-Phe-gLeu-For (IIIa) have been evaluated in in vitro bioassays. Relative to Leu-enkephalin, the modified compounds are more potent in the guinea pig ileum assay and more effectively displace [3H]naloxone from rat brain receptors, while they are generally less potent in the mouse vas deferens assay and only weakly able to displace [3H] (D-Ala2, D-Leu5)enkephalin. The analogs are highly resistant to proteolytic degradation by rat brain membrane preparations that readily hydrolyze Leu-enkephalin.

Fluorescence study on the conformation of a cyclic enkephalin analog in aqueous solution

Conformational parameters of the potent cyclic enkephalin analogs [D-Cys2, D-Cys5]enkephalinamide and [D-Cys2, Trp4, D-Cys5]enkephalinamide were determined by steady-state fluorescence measurements. The very low tyrosine fluorescence quantum yield observed with [D-Cys2, D-Cys5]enkephalinamide reflects a close intramolecular interaction between the phenol ring of Tyr1 and the disulfide bridge. Evaluation of resonance energy transfer between Tyr1 (donor) and Trp4 (acceptor) of [D-Cys2, Trp4, D-Cys5]enkephalinamide on the basis of Förster's equation resulted in an average intramolecular distance of 9.7 +/- 0.2 A between the two aromatic rings. This mean distance is nearly identical with the average Tyr1 - Trp4 distance (9.5 +/- 0.3 A) previously determined with the linear analog [D-Ala2, Trp4, Met5]enkephalin.

Fluorescence study on the solution conformation to dynorphin in comparison of enkephalin

Conformational parameters of the opioid peptides dynorphin and [Leu5] enkephalin in dilute aqueous solution (3 X 10(-5) M) were investigated by performing singlet-singlet energy transfer experiments with dynorphin and with the biologically active 4-tryptophan analogs of dynorphin-(1-13) and [Leu5] enkephalin at pH 5.5 and 8.0. Efficiencies of transfer of excitation energy from the phenol ring of tyrosine (donor) to the indole moiety of tryptophan (acceptor) were determined and average intramolecular Tyr-Trp distances were calculated on the basis of the Förster equation. The observed absence of energy transfer between Tyr1 and Trp14 of dynorphin indicates that the two fluorophores are at least 20 A apart and rules out a close proximity between the N- and C-terminal segments of the peptide. Evaluation of energy transfer in [Trp4] dynorphin-(1-13) resulted in an average intramolecular Tyr1-Trp4 distance of at least 15 A whereas the corresponding average distance in [Trp4, Leu5] enkephalin was found to be much shorter (10 A). It thus appears that in [Trp4] dynorphin-(1-13) the predominant conformation of the N-terminal tetrapeptide segment is almost completely extended, whereas in [Trp4, Leu5] enkephalin folded conformations of that same segment occur in a major proportion. This drastic conformational difference is of interest with regard to the different preferences of dynorphin and [Leu5] enkephalin for the various opiate receptor subclasses.